67th American Society of Hematology Annual Meeting and Exposition (ASH 2025)
06 December - 09 December, 2025, United States
Treatment with mitapivat increased haemoglobin (Hb) levels in children with pyruvate kinase (PK) deficiency who were not receiving regular blood transfusions, according to the ACTIVATE-Kids trial presented at ASH 2025.
Treatment with benralizumab was associated with a significantly reduced risk of flares in patients with hypereosinophilic syndrome (HES) compared with placebo, according to the NATRON study presented at ASH 2025.
